TNFR-1 on tumor cells contributes to the sensitivity of fibrosarcoma to chemotherapy

Abstract

Impaired tumor necrosis factor receptor-1 (TNFR-1) signaling has been found in some malignant tumors with poor prognosis. However, the exact role of TNFR-1 signaling in fibrosarcoma remains unclear. Here, we explored the question by comparing the growth of TNFR-1 deficient (Tnfr1^-) and TNFR-1 competent (Tnfr1⁺) fibrosarcoma FB61 cells (FB61-m and FB61-R1) in mice. TNFR-1 expression on fibrosarcoma cells delayed their growth in vivo but not in vitro. Moreover, reduced FB61-R1 tumor growth was also obtained in T NFR-1 knockout mice. The mechanism relies mainly on the TNFR-1-mediated downregulation of vascular endothelial growth factor (VEGF) production by tumor cells. Importantly, treatment of FB61-m tumors with melphalan resulted in a short delay of tumor growth, followed by a quick r emission. However, when FB61-R1 tumors were treated with melphalan, tumor growth was similarly delayed at first and then completely rejected. Our results reveal evidence for TNFR-1 on tumor cells as a prerequisite in chemotherapy for fibrosarcoma, and provide novel insight into the therapeutic approach against some types of tumors using TNFR-1 angonist.

Keywords

TNFR-1 / fibrosarcoma / chemotherapy

References

[1] Aggarwal, B.B. (2003). Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 3, 745-756 .10.1038/nri1184
[2] Balkwill, F. (2006). TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev 25, 409-416 .10.1007/s10555-006-9005-3
[3] Balkwill, F. (2009). Tumour necrosis factor and cancer. Nat Rev Cancer 9, 361-371 .10.1038/nrc2628
[4] Bauer, S., Oosterwijk-Wakka, J.C., Adrian, N., Oosterwijk, E., Fischer, E., Wuest, T., Stenner, F., Perani, A., Cohen, L., Knuth, A., . (2009). Targeted therapy of renal cell carcinoma: synergistic activity of cG250-TNF and IFNg. Int J Cancer 125, 115-123 .10.1002/ijc.24359
[5] Blankenstein, T., Qin, Z.H., Uberla, K., Muller, W., Rosen, H., Volk, H.D., and Diamantstein, T. (1991). Tumor suppression after tumor celltargeted tumor necrosis factor alpha gene transfer. J Exp Med 173, 1047-1052 .10.1084/jem.173.5.1047
[6] Cabal-Hierro, L., and Lazo, P.S. (2012). Signal transduction by tumor necrosis factor receptors. Cell Signal 24, 1297-1305 .10.1016/j.cellsig.2012.02.006
[7] Coffin, C.M., and Alaggio, R. (2012). Fibroblastic and myofibroblastic tumors in children and adolescents. Pediatr Dev Pathol 15, 127-180 .10.2350/10-12-0944-PB.1
[8] Dong, H.P., Kleinberg, L., Silins, I., Florenes, V.A., Trope, C.G., Risberg, B., Nesland, J.M., and Davidson, B. (2008). Death receptor expression is associated with poor response to chemotherapy and shorter survival in metastatic ovarian carcinoma. Cancer 112, 84-93 .10.1002/cncr.23140
[9] Edelblum, K.L., Goettel, J.A., Koyama, T., McElroy, S.J., Yan, F., and Polk, D.B. (2008). TNFR1 promotes tumor necrosis factor-mediated mouse colon epithelial cell survival through RAF activation of NFkappaB. J Biol Chem 283, 29485-29494 .10.1074/jbc.M801269200
[10] Fan, F., Gray, M.J., Dallas, N.A., Yang, A.D., Van Buren, G., 2nd, Camp, E.R., and Ellis, L.M. (2008). Effect of chemotherapeutic stress on induction of vascular endothelial growth factor family members and receptors in human colorectal cancer cells. Mol Cancer Ther 7, 3064-3070 .10.1158/1535-7163.MCT-08-0615
[11] Ferrara, N., Gerber, H.P., and LeCouter, J. (2003). The biology of VEGF and its receptors. Nat Med 9, 669-676 .10.1038/nm0603-669
[12] Green, D.R., Ferguson, T., Zitvogel, L., and Kroemer, G. (2009). Immunogenic and tolerogenic cell death. Nat Rev Immunol 9, 353-363 .10.1038/nri2545
[13] Kepp, O., Tesniere, A., Schlemmer, F., Michaud, M., Senovilla, L., Zitvogel, L., and Kroemer, G. (2009a). Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis 14, 364-375 .10.1007/s10495-008-0303-9
[14] Kepp, O., Tesniere, A., Zitvogel, L., and Kroemer, G. (2009b). The immunogenicity of tumor cell death. Curr Opin Oncol 21, 71-76 .10.1097/CCO.0b013e32831bc375
[15] Levine, S.J. (2008). Molecular mechanisms of soluble cytokine receptor generation. J Biol Chem 283, 14177-14181 .10.1074/jbc.R700052200
[16] Li, J., Chen, L., and Qin, Z. (2012). Multifaceted tumor stromal fibroblasts. Cancer Microenviron 5, 187-193 .10.1007/s12307-012-0109-8
[17] Li, J., Zhang, W., Jiao, L., Duan, M.H., Guan, H.Z., Zhu, W.G., Tian, Z., and Zhou, D.B. (2011). Combination of melphalan and dexamethasone for patients with newly diagnosed POEMS syndrome. Blood 117, 6445-6449 .10.1182/blood-2010-12-328112
[18] Li, Z., Chen, L., and Qin, Z. (2009). Paradoxical roles of IL-4 in tumor immunity. Cell Mol Immunol 6, 415-422 .10.1038/cmi.2009.53
[19] Li, Z., Jiang, J., Wang, Z., Zhang, J., Xiao, M., Wang, C., Lu, Y., and Qin, Z. (2008). Endogenous interleukin-4 promotes tumor development by increasing tumor cell resistance to apoptosis. Cancer Res 68, 8687-8694 .10.1158/0008-5472.CAN-08-0449
[20] Lu, Y., Yang, W., Qin, C., Zhang, L., Deng, J., Liu, S., and Qin, Z. (2009). Responsiveness of stromal fibroblasts to IFN-gamma blocks tumor growth via angiostasis. J Immunol 183, 6413-6421 .10.4049/jimmunol.0901073
[21] Mocellin, S., Rossi, C.R., Pilati, P., and Nitti, D. (2005). Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev 16, 35-53 .10.1016/j.cytogfr.2004.11.001
[22] Ogata, Y., Matono, K., Mizobe, T., Ishibashi, N., Mori, S., Akagi, Y., Ikeda, S., Ozasa, H., Murakami, H., and Shirouzu, K. (2006). The expression of vascular endothelial growth factor determines the efficacy of post-operative adjuvant chemotherapy using oral fluoropyrimidines in stage II or III colorectal cancer. Oncol Rep 15, 1111-1116 .
[23] Orbach, D., Rey, A., Cecchetto, G., Oberlin, O., Casanova, M., Thebaud, E., Scopinaro, M., Bisogno, G., Carli, M., and Ferrari, A. (2010). Infantile fibrosarcoma: management based on the European experience. J Clin Oncol 28, 318-323 .10.1200/JCO.2009.21.9972
[24] Orbach, D., Rey, A., Oberlin, O., Sanchez de Toledo, J., Terrier-Lacombe, M.J., van Unnik, A., Quintana, E., and Stevens, M.C. (2005). Soft tissue sarcoma or malignant mesenchymal tumors in the first year of life: experience of the International Society of Pediatric Oncology (SIOP) Malignant Mesenchymal Tumor Committee. J Clin Oncol 23, 4363-4371 .10.1200/JCO.2005.12.009
[25] Ouaaz, F., Arron, J., Zheng, Y., Choi, Y., and Beg, A.A. (2002). Dendritic cell development and survival require distinct NF-kappaB subunits. Immunity 16, 257-270 .10.1016/S1074-7613(02)00272-8
[26] Palumbo, A., Bringhen, S., Caravita, T., Merla, E., Capparella, V., Callea, V., Cangialosi, C., Grasso, M., Rossini, F., Galli, M., . (2006). Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367, 825-831 .10.1016/S0140-6736(06)68338-4
[27] Qin, Y., Auh, S., Blokh, L., Long, C., Gagnon, I., and Hamann, K.J. (2007). TNF-alpha induces transient resistance to Fas-induced apoptosis in eosinophilic acute myeloid leukemia cells. Cell Mol Immunol 4, 43-52 .
[28] Qin, Z., and Blankenstein, T. (2000). CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity 12, 677-686 .10.1016/S1074-7613(00)80218-6
[29] Qin, Z., Kruger-Krasagakes, S., Kunzendorf, U., Hock, H., Diamantstein, T., and Blankenstein, T. (1993). Expression of tumor necrosis factor by different tumor cell lines results either in tumor suppression or augmented metastasis. J Exp Med 178, 355-360 .10.1084/jem.178.1.355
[30] Rauert, H., Stuhmer, T., Bargou, R., Wajant, H., and Siegmund, D. (2011). TNFR1 and TNFR2 regulate the extrinsic apoptotic pathway in myeloma cells by multiple mechanisms. Cell Death Dis 2, e194. 10.1038/cddis.2011.78
[31] Riedel, F., Gotte, K., Goessler, U., Sadick, H., and Hormann, K. (2004). Targeting chemotherapy-induced VEGF up-regulation by VEGF antisense oligonucleotides in HNSCC cell lines. Anticancer Res 24, 2179-2183 .
[32] Rivas, M.A., Carnevale, R.P., Proietti, C.J., Rosemblit, C., Beguelin, W., Salatino, M., Charreau, E.H., Frahm, I., Sapia, S., Brouckaert, P., . (2008). TNF alpha acting on TNFR1 promotes breast cancer growth via p42/P44 MAPK, JNK, Akt and NF-kappa B-dependent pathways. Exp Cell Res 314, 509-529 .10.1016/j.yexcr.2007.10.005
[33] Ruegg, C., Yilmaz, A., Bieler, G., Bamat, J., Chaubert, P., and Lejeune, F.J. (1998). Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med 4, 408-414 .10.1038/nm0498-408
[34] Schutze, S., Tchikov, V., and Schneider-Brachert, W. (2008). Regulation of TNFR1 and CD95 signalling by receptor compartmentalization. Nat Rev Mol Cell Biol 9, 655-662 .10.1038/nrm2430
[35] Sha, S., Jin, H., Li, X., Yang, J., Ai, R., and Lu, J. (2012). Comparison of caspase-3 activation in tumor cells upon treatment of chemotherapeutic drugs using capillary electrophoresis. Protein Cell 3, 392-399 .10.1007/s13238-012-2008-7
[36] van Horssen, R., Rens, J.A., Brunstein, F., Guns, V., van Gils, M., Hagen, T.L., and Eggermont, A.M. (2006). Intratumoural expression of TNF-R1 and EMAP-II in relation to response of patients treated with TNF-based isolated limb perfusion. Int J Cancer 119, 1481-1490 .10.1002/ijc.21973
[37] Voron, T., Zinzindohoue, F., Journois, D., Herve, C., Ponzio, O., and Lucas, N. (2012). Hyperthermic isolated liver perfusion with melphalan and bevacizumab. J Visc Surg 150, 60-66 .10.1016/j.jviscsurg.2012.10.018
[38] Wang, D., Montgomery, R.B., Schmidt, L.J., Mostaghel, E.A., Huang, H., Nelson, P.S., and Tindall, D.J. (2009). Reduced tumor necrosis factor receptor-associated death domain expression is associated with prostate cancer progression. Cancer Res 69, 9448-9456 . 10.1158/0008-5472.CAN-09-1903
[39] Wood, L.J., Nail, L.M., Gilster, A., Winters, K.A., and Elsea, C.R. (2006a). Cancer chemotherapy-related symptoms: evidence to suggest a role for proinfl ammatory cytokines. Oncol Nurs Forum 33, 535-542 .10.1188/06.ONF.535-542
[40] Wood, L.J., Nail, L.M., Perrin, N.A., Elsea, C.R., Fischer, A., and Druker, B.J. (2006b). The cancer chemotherapy drug etoposide (VP-16) induces proinfl ammatory cytokine production and sickness behavior-like symptoms in a mouse model of cancer chemotherapy- related symptoms. Biol Res Nurs 8, 157-169 .10.1177/1099800406290932
[41] Wu, X., Wei, H., Zhang, J., and Tian, Z. (2006). Increased uterine NKderived IFN-gamma and TNF-alpha in C57BL/6J mice during early gestation. Cell Mol Immunol 3, 131-137 .
[42] Yoshimura, H., Dhar, D.K., Nakamoto, T., Kotoh, T., Takano, M., Soma, G., and Nagasue, N. (2003). Prognostic significance of tumor necrosis factor receptor in colorectal adenocarcinoma. Anticancer Res 23, 85-89 .
[43] Zhao, X., Rong, L., Li, X., Liu, X., Deng, J., Wu, H., Xu, X., Erben, U., Wu, P., Syrbe, U., . (2012). TNF signaling drives myeloid-derived suppressor cell accumulation. J Clin Invest 122, 4094-4104 .10.1172/JCI64115